Drugs / recombinant fowlpox vector
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT00051454 | Mar 2003 → Feb 2005 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | recombinant fowlpox vector | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00051454 ↗ |
| Modality | Vaccine | “candidate vaccine strategy” NCT00051454 ↗ |
| Route | Other | “active vaccine or placebo injections” NCT00051454 ↗ |